Csl Limited (CSLLY) 36.0500 $CSLLY
Science, Information, And Technology Driving Evolution Of Global Healthcare
PR Newswire - Thu May 14, 8:00AM CDT
Scientific advancements, more readily available medical information and emerging technologies are driving greater patient engagement, improving diagnosis and treatment, and enabling people with life-threatening diseases to live longer and healthier lives, said CSL Limited CEO and Managing Director Paul Perreault. CSL is the parent company of CSL Behring.
CSL: 98.76 (-0.33)
Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 2.68 (-0.01), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), CGEN: 6.45 (-0.03), FGEN: 20.38 (-1.01), GSK: 44.77 (-0.22), ATHX: 1.27 (-0.01)
Global Influenza Vaccine Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9hk3c/global_influenza) has announced the addition of the "Global Influenza Vaccine Market Outlook 2020" report to their offering. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, 2014-2020 Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. . Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Influenza Vaccine - Introduction 4. Global Influenza Vaccine Market Outlook 2020 5. Key Geographical Market 6. Global Influenza Vaccine Market: Pipeline Analysis 7. Global Influenza Vaccine Market: Pricing Analysis 8. Competitive Assessment - Sanofi - GlaxoSmithKline Plc (GSK) - CSL Ltd - AstraZeneca Plc - Sinovac Biotech - Serum Institute of India For more information visit http://www.researchandmarkets.com/research/l9..._influenza
AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), SVA: 5.36 (-0.25)
Is The Elixir Of Youth Closer Than We Think? A New Way Of Viewing Blood Products Companies
Keith Williams - at Seeking Alpha - Tue Mar 31, 10:18AM CDT
BAX: 69.36 (+0.32), BMY: 67.64 (+0.19), GRFS: 32.84 (+0.19)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 37.21 (-0.35), ISIS: 62.55 (+0.10), RGDO: 1.21 (unch)
Global Vaccine Market 2014-2019: Technology Analysis - Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell & Inactivated
M2 - Wed Feb 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/ww4djn/vaccine_market_by) has announced the addition of the "Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019 " report to their offering. The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8% The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market. The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market. On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of market. The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Vaccines Market, By Technology 8 Vaccines Market, By Type 9 Vaccines Market, By Disease Indication 10 Vaccines Market, By End User 11 Global Vaccine Technology Market, By Region 12 Competitive Landscape 13 Company Profiles - Bavarian Nordic - CSL Limited - Emergent Biosolutions, Inc. - Glaxosmithkline, PLC. - Johnson & Johnson - Medimmune, LLC. (A Subsidiary of Astrazeneca) - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - SANOFI For more information visit http://www.researchandmarkets.com/research/ww..._market_by
JNJ: 102.30 (+0.47), EBS: 30.72 (+0.47), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), NVS: 103.75 (-0.15)
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 32.84 (+0.19)
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 37.21 (-0.35), AZN: 69.29 (-0.81), INFI: 12.30 (+0.05), NVS: 103.75 (-0.15)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 69.36 (+0.32), AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 2.33 (-0.01), LXRX: 1.01 (unch), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), MNTA: 20.29 (+0.28)
CSL Issues "Our Corporate Responsibility 2014" Report
PR Newswire - Thu Dec 04, 8:00AM CST
CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report - "Our Corporate Responsibility 2014." The report details the global biopharmaceutical company's performance across key priority areas from July 1, 2013 through June 30, 2014 - recording another strong performance led by CSL Behring.
CSL: 98.76 (-0.33)
Atherosclerosis - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/xjlf7c/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to ehance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences, Inc. - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Boehringer Ingelheim GmbH - Bridge Bioresearch Plc - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CIMAB S.A. - CSL Limited - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - GlaxoSmithKline plc - Isis Pharmaceuticals, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/xj...osclerosis
KNMD: (), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), JNJ: 102.30 (+0.47), ISIS: 62.55 (+0.10), AZN: 69.29 (-0.81), CCXI: 7.21 (-0.09)
Stop Worrying About Ebola: This is a Much More Pressing Concern
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 2:04PM CST
Source: European Commission DG ECHO via Flickr . Despite there being just four reported cases of Ebola in the U.S. this year, including one tragic death, it's been a disease that's garnered months of attention from the American public and...
AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), SNY: 50.52 (-0.27), NVS: 103.75 (-0.15)
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
PR Newswire - Wed Nov 12, 7:00AM CST
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 391.24 (-3.11), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), NVS: 103.75 (-0.15)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 69.36 (+0.32), PFE: 33.99 (+0.05), LLY: 72.90 (-0.16)
Novartis selling flu vaccine unit to CSL for $275M
AP - Mon Oct 27, 11:05AM CDT
NEW YORK (AP) — Australian drugmaker CSL Ltd. said Monday it will buy Novartis' flu vaccine business for $275 million.
CSL: 98.76 (-0.33), NVS: 103.75 (-0.15)
CSL to acquire Novartis' influenza vaccine business
PR Newswire - Mon Oct 27, 7:20AM CDT
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
CSL: 98.76 (-0.33)
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
GSK: 44.77 (-0.22)
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
BAX: 69.36 (+0.32)
Science, Information, And Technology Driving Evolution Of Global Healthcare
PR Newswire - Thu May 14, 8:00AM CDT
Scientific advancements, more readily available medical information and emerging technologies are driving greater patient engagement, improving diagnosis and treatment, and enabling people with life-threatening diseases to live longer and healthier lives, said CSL Limited CEO and Managing Director Paul Perreault. CSL is the parent company of CSL Behring.
CSL: 98.76 (-0.33)
Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 2.68 (-0.01), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), CGEN: 6.45 (-0.03), FGEN: 20.38 (-1.01), GSK: 44.77 (-0.22), ATHX: 1.27 (-0.01)
Global Influenza Vaccine Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9hk3c/global_influenza) has announced the addition of the "Global Influenza Vaccine Market Outlook 2020" report to their offering. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, 2014-2020 Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market. In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. . Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Influenza Vaccine - Introduction 4. Global Influenza Vaccine Market Outlook 2020 5. Key Geographical Market 6. Global Influenza Vaccine Market: Pipeline Analysis 7. Global Influenza Vaccine Market: Pricing Analysis 8. Competitive Assessment - Sanofi - GlaxoSmithKline Plc (GSK) - CSL Ltd - AstraZeneca Plc - Sinovac Biotech - Serum Institute of India For more information visit http://www.researchandmarkets.com/research/l9..._influenza
AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), SVA: 5.36 (-0.25)
Is The Elixir Of Youth Closer Than We Think? A New Way Of Viewing Blood Products Companies
Keith Williams - at Seeking Alpha - Tue Mar 31, 10:18AM CDT
BAX: 69.36 (+0.32), BMY: 67.64 (+0.19), GRFS: 32.84 (+0.19)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 37.21 (-0.35), ISIS: 62.55 (+0.10), RGDO: 1.21 (unch)
Global Vaccine Market 2014-2019: Technology Analysis - Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell & Inactivated
M2 - Wed Feb 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/ww4djn/vaccine_market_by) has announced the addition of the "Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019 " report to their offering. The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8% The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market. The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market. On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of market. The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Vaccines Market, By Technology 8 Vaccines Market, By Type 9 Vaccines Market, By Disease Indication 10 Vaccines Market, By End User 11 Global Vaccine Technology Market, By Region 12 Competitive Landscape 13 Company Profiles - Bavarian Nordic - CSL Limited - Emergent Biosolutions, Inc. - Glaxosmithkline, PLC. - Johnson & Johnson - Medimmune, LLC. (A Subsidiary of Astrazeneca) - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - SANOFI For more information visit http://www.researchandmarkets.com/research/ww..._market_by
JNJ: 102.30 (+0.47), EBS: 30.72 (+0.47), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), NVS: 103.75 (-0.15)
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 32.84 (+0.19)
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 37.21 (-0.35), AZN: 69.29 (-0.81), INFI: 12.30 (+0.05), NVS: 103.75 (-0.15)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 69.36 (+0.32), AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 2.33 (-0.01), LXRX: 1.01 (unch), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), MNTA: 20.29 (+0.28)
CSL Issues "Our Corporate Responsibility 2014" Report
PR Newswire - Thu Dec 04, 8:00AM CST
CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report - "Our Corporate Responsibility 2014." The report details the global biopharmaceutical company's performance across key priority areas from July 1, 2013 through June 30, 2014 - recording another strong performance led by CSL Behring.
CSL: 98.76 (-0.33)
Atherosclerosis - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/xjlf7c/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to ehance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences, Inc. - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Boehringer Ingelheim GmbH - Bridge Bioresearch Plc - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CIMAB S.A. - CSL Limited - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - GlaxoSmithKline plc - Isis Pharmaceuticals, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/xj...osclerosis
KNMD: (), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), JNJ: 102.30 (+0.47), ISIS: 62.55 (+0.10), AZN: 69.29 (-0.81), CCXI: 7.21 (-0.09)
Stop Worrying About Ebola: This is a Much More Pressing Concern
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 2:04PM CST
Source: European Commission DG ECHO via Flickr . Despite there being just four reported cases of Ebola in the U.S. this year, including one tragic death, it's been a disease that's garnered months of attention from the American public and...
AZN: 69.29 (-0.81), GSK: 44.77 (-0.22), SNY: 50.52 (-0.27), NVS: 103.75 (-0.15)
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
PR Newswire - Wed Nov 12, 7:00AM CST
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 391.24 (-3.11), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), NVS: 103.75 (-0.15)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 69.36 (+0.32), PFE: 33.99 (+0.05), LLY: 72.90 (-0.16)
Novartis selling flu vaccine unit to CSL for $275M
AP - Mon Oct 27, 11:05AM CDT
NEW YORK (AP) — Australian drugmaker CSL Ltd. said Monday it will buy Novartis' flu vaccine business for $275 million.
CSL: 98.76 (-0.33), NVS: 103.75 (-0.15)
CSL to acquire Novartis' influenza vaccine business
PR Newswire - Mon Oct 27, 7:20AM CDT
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
CSL: 98.76 (-0.33)
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
GSK: 44.77 (-0.22)
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
BAX: 69.36 (+0.32)
